A recent study by Zhou et al. (42) found that TFCP could ameliorate inflammation in NAFLD mice via reducing the expressions of inflammation-associated genes (IL-1β, TLR4, TNF-α, and IL-6) and enhancing the HNF4α expression. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.